How does piroxicam USP compete with newer NSAIDs in China's pharmaceutical market?

How does piroxicam USP compete with newer NSAIDs in China's pharmaceutical market?
Piroxicam belongs to the oxicam class, distinct from aspirin, ibuprofen, and diclofenac. Its long half-life allows once-daily dosing, a practical advantage for chronic arthritis patients. Yet Chinese clinical discussions increasingly favor meloxicam, also an oxicam, which has a better gastrointestinal safety profile. Piroxicam's role is now largely as a bridge therapy—used when colchicine is contraindicated or ineffective in acute gout—or as a budget option in veterinary medicine, where dosage guidelines still list it for dogs. The drug's age works against it: developed in the 1960s, it predates COX-2 selective agents that dominate new prescriptions. For buyers, this means piroxicam USP demand is stable but not growing, with volumes tied to legacy prescriptions and cost-sensitive segments rather than innovation.